NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

子宮肌瘤栓塞術用設備的全球市場規模,佔有率,COVID-19影響分析(2021年∼2027年)MedCore:微球,PVA粒子市場區隔

Uterine Fibroid Embolization Device Market Size, Share & COVID-19 Impact Analysis | Global | 2021-2027 | MedCore | Segmented by: Microsphere Market & PVA Particle Market

出版商 iData Research Inc. 商品編碼 1010049
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
子宮肌瘤栓塞術用設備的全球市場規模,佔有率,COVID-19影響分析(2021年∼2027年)MedCore:微球,PVA粒子市場區隔 Uterine Fibroid Embolization Device Market Size, Share & COVID-19 Impact Analysis | Global | 2021-2027 | MedCore | Segmented by: Microsphere Market & PVA Particle Market
出版日期: 2021年04月27日內容資訊: 英文
簡介

子宮肌瘤栓塞術(UFE)用設備的全球市場規模,預計在預測期間內增加,2027年達到9,200萬美元。同市場佔有率大部分,由Merit Medical Systems和Boston Scientific所佔。子宮肌瘤栓塞術(UFE),又稱子宮動脈栓塞術,也是對子宮肌瘤使用放射線的療法之一。這個方法不需全身麻醉,適合期盼子宮肌瘤切除術的替代手段的女性。比子宮切除術微創,恢復期間也很短,幾乎也不殘留傷痕。

本報告提供全球子宮肌瘤栓塞術用設備市場的相關調查,市場規模和預測,COVID-19影響分析,成長及阻礙因素,趨勢,合併和收購,競爭情形,產品系列,企業簡介等資訊。

本報告調查對象的地區

  • 北美(美國及加拿大)
  • 南美(巴西,墨西哥,哥倫比亞,阿根廷,秘魯,智利,委內瑞拉,其他)
  • 西歐(德國,法國,義大利,西班牙,瑞士,奧地利,葡萄牙,荷比盧三國,斯堪地那維亞,其他)
  • 中央及東歐(波蘭,土耳其,俄羅斯,希臘,捷克,克羅埃西亞,保加利亞,烏克蘭,哈薩克,匈牙利,羅馬尼亞,波羅的海三小國(愛沙尼亞,拉脫維亞,立陶宛),其他)
  • 中東(沙烏地阿拉伯,阿拉伯聯合大公國,以色列,伊朗,科威特,卡達,巴林,阿曼,其他)
  • 亞太地區(中國,日本,韓國,印度,澳洲,新加坡,印尼,馬來西亞,泰國,菲律賓,汶萊,緬甸,柬埔寨,越南,紐西蘭,台灣,香港等)
  • 非洲(南非,埃及,摩洛哥,迦納,奈及利亞,利比亞,蘇丹,烏干達,肯亞,其他)

包含的市場資料

  • 銷售數,平均銷售價格,市場規模及成長趨勢
  • 手術數量
  • COVID-19影響分析
  • 市場成長及阻礙因素
  • 至2027年的市場預測,及至2017年的成果資料
  • 最近的合併和收購
  • 企業簡介和產品系列
  • 主要的競爭

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: iDATA_GLGYN21_MC_UFE

Throughout this medical market research, the publisher analyzed Uterine Fibroid Embolization Device companies across more than 70 countries and used their comprehensive methodology to understand the Market Sizes, Unit Sold, Average Selling Prices, Company Market Shares, and to create Accurate Forecasts.

Uterine Fibroid Embolization Devices Market Insights

The global uterine fibroid embolization (UFE) device market size is estimated to increase over the forecast period to reach $92 million by 2027.

The majority of the global uterine fibroid embolization device market share was controlled by Merit Medical Systems and Boston Scientific. This global market research spans over 70 countries and includes microsphere procedures and PVA particle procedures.

Uterine fibroid embolization (UFE), also known as uterine artery embolization, is a radiology treatment for fibroids. This procedure does not involve general anesthesia and is appropriate for women who want an alternative to a myomectomy, also known as fibroidectomy. It is a much less invasive way to treat fibroids than a hysterectomy, has a much shorter recovery time, and leaves almost no scarring.

Research Regional Coverage

Throughout this research series, the publisher has covered several regions in great detail. The regions covered are:

  • North America (the United States and Canada)
  • Latin America (Brazil, Mexico, Colombia, Argentina, Peru, Chile, Venezuela, and Other)
  • Western Europe (Germany, France, Italy, Spain, Switzerland, Austria, Portugal, Benelux, Scandinavia, and Other)
  • Central and Eastern Europe (Poland, Turkey, Russia, Greece, Czech Republic, Croatia, Bulgaria, Ukraine, Kazakhstan, Hungary, Romania, Baltic States (Estonia, Latvia, and Lithuania), and Other)
  • Middle East (Saudi Arabia, UAE, Israel, Iran, Kuwait, Qatar, Bahrain, Oman, and Other)
  • Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Brunei, Myanmar, Cambodia, Vietnam, New Zealand, Taiwan, Hong Kong, and Other)
  • Africa (South Africa, Egypt, Morocco, Ghana, Nigeria, Libya, Sudan, Uganda, Kenya, and Other)

MARKET DATA INCLUDED

  • Unit Sales, Average Selling Prices, Market Size & Growth Trends
  • Procedure Numbers
  • COVID-19 Impact Analysis
  • Market Drivers & Limiters
  • Market Forecasts Until 2027, and Historical Data to 2017
  • Recent Mergers & Acquisitions
  • Company Profiles and Product Portfolios
  • Leading Competitors